“115” and “214” Cements by G-I Holdings

Product Description

G-I Holdings manufactured two pipe insulation cement products — designated the “115” Cement and the “214” Cement — that were produced and sold across industrial markets from approximately 1937 through 1975. These cements were engineered as high-temperature insulating compounds applied to pipe systems, boilers, and related industrial infrastructure. Products in this category were widely used in refineries, chemical plants, power generation facilities, shipyards, and heavy manufacturing environments where thermal management of piping systems was a critical operational requirement.

Insulating cements of this type were typically mixed with water on-site to form a workable paste or trowelable compound, then applied directly to pipe surfaces, fittings, and equipment before being allowed to cure. The cured material formed a rigid, heat-resistant insulating shell designed to reduce heat loss, protect personnel from contact burns, and maintain process temperatures in industrial systems. Because these products were sold over a span of nearly four decades — covering the post-World War II industrial expansion through the early 1970s — they reached a large and geographically broad population of industrial workers across multiple generations of the American manufacturing workforce.

G-I Holdings, through its corporate history and predecessor entities, was an established participant in the industrial insulation products market during the mid-twentieth century. The “115” and “214” designations identified distinct formulations within the company’s cement product line, each likely engineered to meet specific temperature ratings, application characteristics, or industry specifications.

Asbestos Content

Both the “115” and “214” Cements contained chrysotile asbestos as a component of their formulation. Chrysotile, sometimes referred to as white asbestos, is a serpentine mineral fiber that was extensively incorporated into insulating cements and similar refractory products throughout the mid-twentieth century. Its heat resistance, tensile strength, and binding properties made it functionally attractive for manufacturers producing high-temperature industrial insulation.

In insulating cement formulations, chrysotile fibers were typically combined with binders, fillers, and other materials to produce a compound that could withstand sustained thermal stress without cracking or degrading. The asbestos fiber matrix contributed structural integrity to the cured product and was an intentional component of the product’s design — not an incidental contaminant.

Chrysotile asbestos is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC). Regulatory frameworks including the Occupational Safety and Health Administration (OSHA) asbestos standards and the Asbestos Hazard Emergency Response Act (AHERA) recognize all commercial forms of asbestos, including chrysotile, as presenting serious health risks upon fiber release and inhalation. There is no established safe level of occupational asbestos exposure recognized under current scientific or regulatory consensus.

How Workers Were Exposed

Industrial workers who handled, mixed, applied, or disturbed the “115” and “214” Cements faced potential exposure to airborne chrysotile asbestos fibers at multiple points throughout the product lifecycle.

Mixing and preparation represented a primary exposure pathway. When dry cement powder was combined with water, the agitation involved in mixing could release asbestos fibers into the breathing zone of the worker performing the task. Industrial environments of the mid-twentieth century generally lacked the respiratory protection, engineering controls, and hygiene protocols that are now mandated under OSHA’s asbestos standards.

Application and troweling carried additional exposure risk. Workers who spread and shaped the wet cement compound onto pipe surfaces worked in close proximity to the material for extended periods, and any fiber release during the manipulation of the product could result in inhalation.

Cutting, trimming, and finishing of cured insulation cement — whether during original installation or during later repair and maintenance work — was particularly hazardous. Dry, cured asbestos-containing cement is friable and generates visible dust when cut, abraded, or broken. Workers performing maintenance on pipe systems insulated with these products, including pipefitters, boilermakers, and general industrial maintenance personnel, could disturb previously applied material and release concentrated quantities of asbestos fiber.

Bystander exposure was also a documented concern in industrial settings. Workers in adjacent areas of a plant or facility where cement mixing or application was underway may have inhaled fibers without directly handling the product themselves.

The latency period for asbestos-related diseases — the interval between first exposure and the emergence of clinical illness — typically spans 20 to 50 years. This means that workers exposed to “115” and “214” Cements during the product’s years of production may be presenting with or have recently received diagnoses of asbestos-related illness decades after their last occupational contact with these materials.

Diseases associated with occupational asbestos exposure include mesothelioma (a cancer of the pleural and peritoneal linings), lung cancer, asbestosis (progressive scarring of lung tissue), and other pulmonary conditions. Mesothelioma in particular is strongly associated with asbestos exposure and has no established causal pathway that does not involve asbestos fiber inhalation.

Documented Trust Fund / Legal Options

G-I Holdings does not have an associated asbestos bankruptcy trust fund. Accordingly, claims related to the “115” and “214” Cements fall into Tier 2 — Litigation, meaning that legal remedies are pursued through civil litigation in state or federal courts rather than through a structured trust fund claims process.

Litigation records document that claims have been filed against G-I Holdings and related corporate entities in connection with asbestos-containing products. Plaintiffs alleged that exposure to asbestos-containing cements and insulation products manufactured or distributed by the company caused serious and life-threatening illness, including mesothelioma and lung cancer. Plaintiffs further alleged that the company knew or should have known of the hazards associated with asbestos exposure during the relevant production period and failed to adequately warn workers of those risks.

Industrial workers generally — including those employed in refineries, power plants, manufacturing facilities, and other heavy industry settings where pipe insulation cements were routinely used — are among those documented in litigation records as having alleged exposure to G-I Holdings products.

Individuals diagnosed with mesothelioma, lung cancer, asbestosis, or related conditions who have a documented occupational history that includes work with or around pipe insulation cements from this period should consult with a qualified asbestos litigation attorney. An attorney experienced in asbestos claims can evaluate:

• Work history and exposure documentation, including employer records, coworker testimony, and product identification evidence
• Applicable statutes of limitations, which vary by state and typically run from the date of diagnosis rather than the date of exposure
• Potential defendant identification, including manufacturers, distributors, and premises owners who may share liability
• Coordination with other claims, including any trust fund claims arising from exposure to products by other manufacturers

Because G-I Holdings does not maintain a trust fund, civil litigation is the primary avenue for financial recovery. Outcomes in asbestos litigation vary based on jurisdiction, the strength of exposure documentation, and the specific disease diagnosis. Legal consultation should be sought promptly following a diagnosis, given the time-sensitive nature of applicable filing deadlines.

This article is provided for informational and reference purposes only. It does not constitute legal advice. Individuals seeking legal counsel regarding asbestos exposure claims should consult a licensed attorney.